Tiziana Life Sciences (TLSA) said Thursday it does not intend to embark on any capital raising activity "for the immediate future."
The company said the decision comes after the news that came out on Wednesday about the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis treated with nasal foralumab.
Tiziana said it continues to be committed to delivering shareholder value and advancing its drug candidates via clinical trials and regulatory processes.
Tiziana shares fell 10% in recent trading.
Price: 0.72, Change: -0.08, Percent Change: -10.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.